title: [Medical treatment of children with infantile haemangiomas].
abstract: Infantile haemangioma is a benign vascular tumour seen in 4-5% of infants. It has a characteristic life cycle comprised by a proliferative phase and a spontaneous involution phase. Most infantile haemangiomas do not require intervention. Treatment is relevant when there is a risk of functional impairment or cosmetic disfigurement, or if the haemangiomas are painful and ulcerating. The beta blocker propranolol has been shown to be an excellent first-line treatment, and we present an algorithm for therapeutic decision and monitoring.
authors.affiliation: anette.bygum@rsyd.dk.
authors.forename: Hanne Kalleklev
authors.initials: HK
authors.lastname: Velure
authors.forename: Ulla Birgitte
authors.initials: UB
authors.lastname: Hartling
authors.forename: Anette
authors.initials: A
authors.lastname: Schuster
authors.forename: Annette
authors.initials: A
authors.lastname: Bygum
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000465:Algorithms; D003937:Diagnosis, Differential; D006391:Hemangioma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007223:Infant; D011433:Propranolol / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000319:Adrenergic beta-Antagonists; D011433:Propranolol